Nivolumab toxicity
Evidence-based neurology checklist on nivolumab toxicity: Peripheral neurological features Peripheral adverse events Guillain Barre syndrome (GBS) Hypokalaemic paralysis Myasthenia gravis (MG) Lambert Eaton myasthenic syndrome (LEMS) Myositis Rhabdomyolysis Central neurological features Endocrine…
Peripheral neurological features
- Peripheral adverse events
- Guillain Barre syndrome (GBS)
- Hypokalaemic paralysis
- Myasthenia gravis (MG)
- Lambert Eaton myasthenic syndrome (LEMS)
- Myositis
- Rhabdomyolysis
Central neurological features
Endocrine features
Dermatological features
Cardiac features
Renal features
Gastrointestinal features
Other features
References
- Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016; 29:806-812.
- Izzedine H, Mateus C, Boutros C, et al. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 2017; 32:936-942.
- Supakornnumporn S, Katirji B. Guillain-Barré syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis 2017; 19:80-83.
- Barbacki A, Maliha PG, Hudson M, Small D. A case of severe pembrolizumab-induced neutropenia. Anticancer Drugs 2018; 29:817-819.
- Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016; 46:86-88.
- And 33 more. Subscribe to see the full list
